Intergroup Exemestane Study mature analysis: overall survival data.
about
Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineA systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancerPharmacogenetic testing affects choice of therapy among women considering tamoxifen treatmentAtrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Clinical practice decisions in endocrine therapy.Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.
P2860
Intergroup Exemestane Study mature analysis: overall survival data.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Intergroup Exemestane Study mature analysis: overall survival data.
@ast
Intergroup Exemestane Study mature analysis: overall survival data.
@en
type
label
Intergroup Exemestane Study mature analysis: overall survival data.
@ast
Intergroup Exemestane Study mature analysis: overall survival data.
@en
prefLabel
Intergroup Exemestane Study mature analysis: overall survival data.
@ast
Intergroup Exemestane Study mature analysis: overall survival data.
@en
P1433
P1476
Intergroup Exemestane Study mature analysis: overall survival data.
@en
P2093
International Exemestane Study Group
P356
10.1097/01.CAD.0000277608.23376.BC
P478
19 Suppl 1
P50
P577
2008-02-01T00:00:00Z